Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Cholesterol lowering, sudden cardiac death and mortality.

de Lorgeril M, Salen P.

Scand Cardiovasc J. 2008 Aug;42(4):264-7. doi: 10.1080/14017430801993206. Review.

PMID:
18615354
2.

Cholesterol lowering and mortality: time for a new paradigm?

de Lorgeril M, Salen P.

Nutr Metab Cardiovasc Dis. 2006 Sep;16(6):387-90. Epub 2006 Jul 26.

PMID:
16875805
3.

Cholesterol lowering and mortality: a great success story!

Trevisan M, Stranges S.

Nutr Metab Cardiovasc Dis. 2006 Sep;16(6):391-4. Epub 2006 Jul 26. No abstract available.

PMID:
16875804
4.

Lovastatin to prevent acute coronary events with average cholesterol levels.

MacFarlane LL, Carek PJ.

J Fam Pract. 1998 Aug;47(2):91-2. No abstract available.

PMID:
9722787
6.

Cholesterol, primary and secondary prevention, and all-cause mortality.

Criqui MH.

Ann Intern Med. 1991 Dec 15;115(12):973-6.

PMID:
1835327
7.
8.

Cholesterol and coronary heart disease mortality.

Sleight P.

Aust N Z J Med. 1992 Oct;22(5 Suppl):576-9. Review.

PMID:
1449442
10.

Prevention of sudden death in patients with coronary artery disease: do lipid-lowering drugs play a role?

De Sutter J, Firsovaite V, Tavernier R.

Prev Cardiol. 2002 Fall;5(4):177-82. Review.

11.

[Sudden cardiac death (SCD) and guidelines for SCD].

Andresen D.

Z Kardiol. 2004;93 Suppl 1:I4-6. German.

PMID:
15021998
12.

Possible role of beta-blockers in the prevention of sudden cardiac death (SCD) in patients with coronary heart disease (CHD).

Lamaida N, Capuano V, Di Mauro G, Aucello G, Scotto Di Quacquaro G.

Panminerva Med. 1994 Jun;36(2):71-5. Review.

PMID:
7831062
13.

Cholesterol and coronary heart disease: screening and treatment.

Turner-Boutle M.

Nurs Times. 1998 Apr 15-21;94(15):46-7.

PMID:
9615661
14.

[Sudden cardiac death in hypertension].

von Brandis P, Kjeldsen SE, Gjesdal K.

Tidsskr Nor Laegeforen. 1997 Jun 20;117(16):2337-40. Review. Norwegian.

PMID:
9265281
15.
16.

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.

Preiss D, Sattar N.

Clin Endocrinol (Oxf). 2009 Jun;70(6):815-28. doi: 10.1111/j.1365-2265.2008.03490.x. Epub 2008 Dec 3. Review.

PMID:
19067719
17.

Future trends in the treatment of dyslipidemia. Introduction.

Stein EA.

Postgrad Med. 2002 Oct;112(4 Suppl):4-5. doi: 10.3810/pgm.10.2002.suppl20.104.

PMID:
19667593
18.

Effects of lipid-altering therapies on ventricular arrhythmias and sudden cardiac death.

Majmudar MD, Tompkins C, Bachmann JM, Blumenthal RS, Marine JE.

Cardiol Rev. 2009 Mar-Apr;17(2):60-9. doi: 10.1097/CRD.0b013e3181861be8. Review.

PMID:
19367147
19.

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.

Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators.

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

PMID:
19318984
20.

Clinical prevention of coronary heart disease through cholesterol-lowering therapy.

Grundy SM.

Curr Ther Endocrinol Metab. 1997;6:520-6. Review. No abstract available.

PMID:
9174799

Supplemental Content

Support Center